BioSpace News Archive

Cognition Therapeutics, Inc., a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that it has commenced an underwritten public offering of shares of its common stock.

Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2023.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California

CareDx, Inc. announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.

Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug and pediatric exclusivity to CRESEMBA® (isavuconazonium sulfate) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region.

Ranok Therapeutics Expands Clinical Testing of CHAMP ® BRD4 Protein Degrader RNK05047 to China.

The College of American Pathologists, the world’s leading organization of board-certified pathologists, announced that Michael Fraser, PhD, MS, CAE, FCPP, is joining the CAP as its new Chief Executive Officer.

Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose.